Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.49 |
| ▸ | SCD | O00767 | 8/20 | 0.43 |
| ▸ | SRPK1 | Q96SB4 | 3/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767688 | 0.91 | SCD (0.50) | HDAC1SCD | |
| SCHEMBL1767464 | 0.90 | HDAC1 (0.49) | HDAC1SCDKDM1AROCK2RORC | |
| SCHEMBL1767462 | 0.90 | SCD (0.41) | HDAC1SCD | |
| SCHEMBL17263335 | 0.88 | SCD (0.42) | HDAC1SCDKDM1A | |
| SCHEMBL1767539 | 0.88 | ROCK2 (0.42) | HDAC1SCDROCK2 | |
| SCHEMBL16160216 | 0.87 | HDAC1 (0.48) | HDAC1SCDKDM1AROCK2 | |
| SCHEMBL1767456 | 0.86 | HDAC1 (0.49) | HDAC1SCDSRPK1KDM1AROCK2 | |
| SCHEMBL1767455 | 0.85 | HDAC1 (0.52) | HDAC1SCDKDM1A | |
| SCHEMBL1767627 | 0.85 | SCD (0.56) | HDAC1SCDKDM1ARORC | |
| SCHEMBL1767552 | 0.85 | HDAC1 (0.48) | HDAC1SCDKDM1AROCK2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160289191-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-10-06 | — | — | US | claimed |
| CN-102119152-B | Organic compounds | NOVARTIS AG | 2014-07-02 | — | — | CN | claimed |
| CN-102119152-A | Organic compounds | NOVARTIS AG | 2011-07-06 | — | — | CN | claimed |
| US-20110105530-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-05 | — | — | US | claimed |
| US-20160289191-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| US-20160289191-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| US-20160289191-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| US-9187426-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-11-17 | — | — | US | disclosed |
| US-9187426-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-11-17 | — | — | US | disclosed |
| US-9150527-B2 | Metalloenzyme inhibitor compounds | INNOCRIN PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150527-B2 | Metalloenzyme inhibitor compounds | INNOCRIN PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140303157-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140303157-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2014-10-09 | — | — | US | disclosed |
| US-20110105530-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| US-20110105530-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| WO-2009156484-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105530-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | HDAC1 136/4885SCD 1/4885SRPK1 2164/4885 |
| US-20140303157-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | HDAC1 782/4885SCD 1085/4885SRPK1 3747/4885 |
| US-20160289191-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | HDAC1 136/4885SCD 1/4885SRPK1 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.